Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Cerebral Palsy, Brachial Plexus; Injury, Newborn
Interventions: Magnetoencephalography (MEG), Electroencephalography (EEG), Transcranial Magnetic Stimulation (TMS); Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Hypertension, Diabetes Mellitus, Type 2
Interventions: Overstitch Endoscopic Suture System, Lifestyle Intervention; Device · Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 65 Years
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 9
States / cities: Orlando, Florida • Chicago, Illinois • Evanston, Illinois + 6 more

Conditions: Cataract, Age-related Cataract, Circadian Rhythm Disorders, Glaucoma, Age Related Macular Degeneration
Interventions: Blue-light filtering intraocular lens, Conventional intraocular lens; Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years and older
Enrollment: 10,192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Alzheimer Disease
Interventions: LY3303560 - IV, Placebo - IV, Florbetapir F 18, Flortaucipir F18; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: Melbourne, Florida • Orlando, Florida • Port Orange, Florida + 2 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Secondary Hypogonadism
Interventions: Androxal (enclomiphene citrate), Testosterone; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Androgen Axis Suppression, Prostatectomy, Prostate Cancer
Interventions: Apalutamide, Androgen Deprivation Therapy; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 6
States / cities: Gilbert, Arizona • Chicago, Illinois • Kansas City, Kansas + 3 more

Conditions: Caries, Unsatisfactory or Defective Restoration of Tooth
Interventions: Placement of restoration; Device
Lead sponsor: Heraeus Kulzer GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Heart Failure
Interventions: CLP, placebo; Drug
Lead sponsor: Sorbent Therapeutics; Industry
Eligibility: 21 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tustin, California

Conditions: Spontaneous Pneumothorax
Interventions: Simple Aspiration, Surgeon Preference; Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 12 Years to 17 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hair Thinning
Interventions: Nutrafol Vegan Women's Hair Supplement; Dietary Supplement
Lead sponsor: Nutraceutical Wellness Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Manhattan Beach, California • Sacramento, California

Conditions: Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF), Primary Myelofibrosis (PMF)
Interventions: Bomedemstat; Drug
Lead sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Neoplasm
Interventions: RAD001, Letrozole 2.5mg, Letrozole 2.5mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 10
States / cities: Springdale, Arkansas • Long Beach, California • San Francisco, California + 7 more

Conditions: Gastric Cancer, Gastrointestinal Cancer, HER2 Gene Mutation
Interventions: Neratinib Pill, Fam-Trastuzumab Deruxtecan-Nxki (TDxD); Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Palo Alto, California • Buffalo, New York • Philadelphia, Pennsylvania

Conditions: Pain, Spinal Cord Injuries, Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Insomnia Disorder
Interventions: Daridorexant 10 mg, Daridorexant 25 mg, Daridorexant 50 mg, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 804 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 53
States / cities: Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 47 more

Conditions: Advanced Solid Tumors Cancer
Interventions: Livmoniplimab, Budigalimab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 21
States / cities: Springdale, Arkansas • Duarte, California • Irvine, California + 16 more

Conditions: Atopic Dermatitis, Type 1 Hypersensitivity
Interventions: STMC-103H, Placebo; Biological
Lead sponsor: Siolta Therapeutics, Inc.; Industry
Eligibility: 0 Days to 14 Days
Enrollment: 283 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 24
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: CCSVI, Chronic Cerebrospinal Venous Insufficiency, Venous Malformations of CNS Draining Veins
Interventions: venous angioplasty; Procedure
Lead sponsor: Hubbard Foundation; Other
Eligibility: 18 Years to 70 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 9
States / cities: Downey, California • Oceanside, California • Atlanta, Georgia + 6 more

Conditions: Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma, T-Cell Large Granular Lymphocyte Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Rituximab, Total-Body Irradiation; Procedure · Drug · Other + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 3
States / cities: Rochester, Minnesota • Seattle, Washington

Conditions: Extremity Injury
Interventions: pre-hospital tourniquet placement; Other
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Allergy, Peanut
Interventions: ligelizumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 55 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 29
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 23 more

Conditions: Acute Lymphoblastic Leukemia
Interventions: Tisagenlecleucel; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois • Kansas City, Missouri + 1 more

Conditions: Patent Ductus Arteriosus
Interventions: feeding, fasting; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 23 Weeks to 33 Weeks
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 14
States / cities: San Francisco, California • San Jose, California • Chicago, Illinois + 11 more

Search by objective public record fields.

Multi-modal Neuroimaging in Children With Cerebral Palsy or Brachial Plexus Birth Palsy

Multicenter Endoscopic Sleeve Gastrectomy (ESG) Trial (MERIT Trial)

Association Between Light Spectrum and Survival After Cataract Surgery

A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease

Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance

The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

Comparison of 2 Different Resin Based Filling Materials in Posterior Teeth - a Multicenter Study

Evaluation of Cross-Linked Polyelectrolyte (CLP) With Placebo in Heart Failure Subjects

Spontaneous Pneumothorax in Children

Nutraceutical Supplement With Vegan Botanicals in Females With Self-Perceived Thinning Hair

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Cognitive Testing for the Pain Quality Assessment Scale (PQAS)

Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Allergic Disease Onset Prevention Study

Multi-center Registry for CCSVI Testing and Treatment

Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Pre-hospital Tourniquet in Extremity Injury

Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)

Feeding During Ibuprofen or Indomethacin Treatment of Preterm Infants